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Abstract
Background: Several criteria exist to identify the optimal model for quantification of
tracer kinetics. The purpose of this study was to evaluate the correspondence in
kinetic model preference identification for brain PET studies among five model
selection criteria: Akaike Information Criterion (AIC), AIC unbiased (AICC), model
selection criterion (MSC), Schwartz Criterion (SC), and F-test.
Materials and Methods: Six tracers were evaluated: [11C]FMZ, [11C]GMOM,
[11C]PK11195, [11C]Raclopride, [18F]FDG, and [11C]PHT, including data from five
subjects per tracer. Time activity curves (TACs) were analysed using six plasma input
models: reversible single-tissue model (1T2k), irreversible two-tissue model (2T3k),
and reversible two-tissue model (2T4k), all with and without blood volume fraction
parameter (VB). For each tracer and criterion, the percentage of TACs preferring a
certain model was calculated.
Results: For all radiotracers, strong agreement was seen across the model selection
criteria. The F-test was considered as the reference, as it is a frequently used
hypothesis test. The F-test confirmed the AIC preferred model in 87% of all cases.
The strongest (but minimal) disagreement across regional TACs was found when
comparing AIC with AICC. Despite these regional discrepancies, same preferred
kinetic model was obtained using all criteria, with an exception of one FMZ subject.
Conclusion: In conclusion, all five model selection criteria resulted in similar
conclusions with only minor differences that did not affect overall model selection.
Keywords: Positron emission tomography, Brain imaging, Molecular imaging,
Pharmacokinetics, Imaging
Background
The full potential of a novel PET tracer can only be achieved when the uptake or clear-
ance of the tracer can be extracted from the normal activity distribution of the
dynamic PET data. To evaluate this, a pharmacokinetic model describing the tracer in
vivo kinetics is necessary. With a kinetic model, the in vivo physiological behaviour of
the tracer both in tissue and blood can be described. The model that best describes the
kinetic behaviour of the tracer may be used to reproducibly and reliably quantify tracer
distribution or binding. Finding the optimal model can, however, be a challenge.
Several criteria exist to identify the preferred kinetic model that provides the best fit
to the time course of the tissue tracer concentration [1], [2], [3], [4], [5]. Each of these
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criteria ranks the quality of the model fit and thus provides a means for model selec-
tion. These criteria are all based on the goodness of fit (sum of squared differences be-
tween measured and estimated data, also termed residuals) and the complexity of the
model (number of fit parameters). In addition, both number of frames and weighting
factors applied to residuals are taken into account. The various criteria have substantial
similarities in their equations and parameters used (Eqs. 1–4). For example, Eq. 3 can
be written as the difference between ln of nominator and denominator; this now is
quite similar to other equations. The only difference is in the penalty parameter (added
based on the complexity of model) in these equations. We therefore hypothesize that
these criteria would result in (overall) comparable model preferences in actual clinical
data. To the best our knowledge, a direct comparison of their performance in clinical
PET brain studies has never been reported and the selection of the criterion used is
frequently a matter of debate.
The purpose of the present study was to evaluate the similarity and/or difference in
model preference for several commonly used criteria: Akaike Information Criterion
(AIC) [6], [1], AIC unbiased (AICC) [7], [2], Model Selection Criterion (MSC) [8], [3],
Schwartz Criterion (SC) [9], [4], and finally validate them against the F-test [10], [5]. To
cover a range of kinetics, these criteria were used to identify the preferred model for
six tracers with known differences in kinetic (in vivo) properties.
Methods
Six neuroPET tracers with different kinetic properties were evaluated: [11C]Flumazenil
([11C]FMZ), [11C]N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxy-phenyl)-N′-methylgua-
nidine ([11C]GMOM), [11C](1-[2-chlorophenyl]-N-methylN-[1-methyl-propyl]-3-isoquinoline
carboxamide) ([11C]PK11195), [11C]Raclopride, [18F]Fluorodeoxyglucose ([18F]FDG), and
[11C]Phenytoin ([11C]PHT). GABA (A) receptor binding, NMDA receptor binding, TSPO
binding, dopamine receptor binding, metabolic rate of glucose, and function of Pgp trans-
porters can be deduced using the following PET tracers: [11C]FMZ, [11C]GMOM,
[11C]PK11195, [11C]raclopride, [18F]FDG, and [11C]PHT, respectively. Additional file 1: Figure
S1 illustrates typical whole brain gray matter time activity curves (TACs) of the six tracers. A
full description of the original studies has been reported previously for [11C]FMZ [11],
[11C]PK11195 [12], [11C]Raclopride [13], [18F]FDG [14], [11C]GMOM [15], and [11C]PHT
[1]. For each tracer, PET scan data from five subjects were included. Subjects were randomly
selected from existing databases, and researchers had no information on group status (both
healthy subjects and patients). Five subjects per tracer reflect the number of subjects often
included in first-time studies examining tracer kinetics. Each of these subjects had a T1-
weighted magnetic resonance imaging (MRI) scan and a metabolite corrected arterial input
function was also available. For scanner properties, attenuation correction, scan duration,
and reconstruction methods, see Table 1. All scans were corrected for dead time, randoms,
scatter, and decay. The original studies had all been approved by the Medical Ethics Review
Committee of the VU University Medical Center. All subjects had provided written informed
consent after complete explanation of the study procedures.
For anatomical delineation of volumes of interest (VOIs), MRI was used. Subjects’
T1-weighted MRI scan was co-registered with the summed PET data using VINCI
software (Cologne, Germany). The co-registered MRI scan was segmented into gray
matter, white matter, and extra-cerebral fluid, and TACs were extracted using PVElab
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[16] in combination with the Hammers template [17]. Sixty-eight gray matter VOIs
were delineated onto MRI, i.e. 68 TACs were extracted per subject. TACs were analysed
using six plasma input models: a reversible single-tissue model (1T2k), an irreversible
two-tissue model (2T3k), and a reversible two-tissue model (2T4k), all three both with
and without additional blood volume parameter (VB) [18].
For all six tracers, the preferred models across TACs were obtained using various
model selection criteria. Equations below show the implementation of the various
model selection criteria. Akaike Information Criterion (AIC) [[6]; Equation (Eq.) 1],
AIC unbiased (AICC) [[7]; Eq. 2], Model Selection Criterion (MSC) [[8]; Eq. 3],
Schwartz Criterion (SC) [[9]; Eq. 4], and the F-test [[10]; Eq. 5].
AIC ¼ n ln
X
i
wi y tið Þ−y tið Þð Þ2=n
 
þ 2p ð1Þ
AICC ¼ n ln
X
i
wi y tið Þ−y tið Þð Þ2=n
 





iwi y tið Þ−y tið Þ½ 2P
iwi y tið Þ−y tið Þ½ 2
−2p=n ð3Þ
SC ¼ n ln
X
t
wi y tið Þ−y tið Þ½ 2=n
 
þ p ln nð Þ ð4Þ
F ¼ Q1−Q2ð Þ= p2−p2ð Þ
Q2= n−p2ð Þ
ð5Þ
where n represents the number of observations, p the number of parameters, wi the
weight applied to residual of ith acquisition, y are the measured values (PET scan), ŷ
are the predicted (fitted) values, y is the mean of the measured values, and ti time of
ith acquisition. For the F-test, Q1 represents the sum of squares for the model with p1
parameters, and Q2 the sum of squares of model with p2 parameters, where p1 < p2 is
required. wi (wi = 1/σi
2) was estimated using the following equation [19]:
Table 1 Overview of retrospective datasets used
[11C]FMZ [11C]PK11195 [11C]Raclopride [18F]FDG [11C]GMOM [11C]PHT
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ECAT EXACT HR+ scanner (CTI/Siemens, Knoxville, TN, USA). Gemini TF-64 PET/CT scanner (Philips Medical Systems,
Cleveland, OH, USA). Philips Intera 1.5 T scanner (Philips Medical Systems, Best, The Netherlands). Siemens Sonata 1.5 T &
Siemens 1.0 T IMPACT (Siemens, Erlangen, Germany)
3-D RAMLA three-dimensional row action maximum likelihood reconstruction algorithm, OSEM ordered subset
expectation maximization
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σ2 ¼ α∙dcf ∙dcf TL∙L , where σ2represents the variances for each frame and is calculated
based on the whole scanner trues counts (T); dcf is the decay correction factor, L repre-
sents frame length, and α is the proportionality constant signifying the variance level.
For, AIC, AICC, and SC, a lower value implies a better fit. Therefore, the lowest value ob-
tained from the model selection criterion indicates the preferred kinetic model, i.e. the
model that provides the best fit to a TAC with the smallest number of model parameters.
For MSC, a higher value implies a better fit and hence the highest value will be indicative of
the most appropriate model. F-test directly compares two models and returns a F-statistic
with p2-p1 and n-p2 degrees of freedom. If this F-statistic is larger than the tabulated value
at a specified p value, the complex model has a better fit (with a significance of p < 0.05).
Agreement of the model selection criteria was evaluated by calculating the percentage
preference for a kinetic model across all TACs. This was performed for all subjects and
for each model selection criteria and tracer. The F-test was considered as the reference
for model comparison as it is a frequently used hypothesis test [20], [21]. This F-test,
however, is difficult to apply when comparing multiple models, subjects, TACs, and
tracer studies. For example, in the present study, this would have resulted in 61,200
comparisons (30 comparisons per tracer per subject per VOI). Therefore, a more
pragmatic approach was followed by first identifying the most likely plausible model
based on known tracer kinetics, visual inspection of the fits, and AIC results, which
can be calculated very efficiently. Next, the F-test was applied to determine if this
model was the preferred one (per TAC) when compared to all other models. Finally,
regional agreement/disagreement of AICC, SC, and MSC to AIC and eventually F-test
was evaluated. To examine if any existent disagreement between model selection
criteria was a general effect or driven by a single subject, the frequency of model
preferences per subject were also evaluated for each model selection criteria. Finally, in
order to examine the effect of VOI size (assuming that smaller VOIs result in TACs
with higher noise levels) on the model selection criteria, similar analyses were
performed for VOIs with sizes smaller and larger than 5 mL separately.
Results
For all six radiotracers, strong agreement was observed between the different model
selection criteria when examining the frequency of model preferences across all TACs
(Fig. 1). Only one small deviation was observed for FMZ: AICC preferred 2T3k_VB,
whereas the other model selection criteria preferred 2T4k_VB. The reduced regional
agreement for FMZ when comparing AIC with AICC turned out to be an 18% differ-
ence in model preference. When examining within subject preference, it was shown
that this difference was mainly driven by one subject. For this subject, 2T3k_VB was
preferred according AICC and F-test where AIC, MSC, and SC all preferred 2T4k_VB
for this subject. For the other remaining four FMZ studies, all five criteria agreed on
2T4k_VB being the preferred model for FMZ.
Even though all model selection criteria agreed on the preferred model across TACs
(with exception of one FMZ study), slight disagreements between criteria did exist. The
F-test confirmed the AIC preferred models within single subjects for 87% of all cases.
AIC and MSC gave exactly the same model preferences for all the tracers studied.
Regional disagreement of only 13 and 7% for AICC and SC, respectively, with AIC was
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observed for [11C]PK11195. In case of [11C]Raclopride, regional disagreement of 22%
when comparing AIC with AICC and 10% between AIC and SC was observed. For
[18F]FDG, relatively low disagreement of 4 and 6% for AICC and SC, respectively, was
observed. A relatively low (4%) disagreement of AIC with both AICC and SC (4%) was
obtained for [11C]GMOM. A regional disagreement of 16% for AICC and 9% for SC
with AIC was seen for [11C]PHT. Despite regional differences, and between subject
deviations, all model selection criteria showed strong agreement in model preference.
Effect of noise on the model preference can be observed in Figs. 2 and 3. For all the
tracers, a variation in the model preference is observed with varying VOI size, which is pri-
marily due to noise. However, the VOI size (either smaller or larger than 5 mL), in general,
did not have a notable effect on the agreement of the model selection criteria (Figs. 2 and 3).
Discussion
The aim of the present study was to assess the overall agreement and/or disagreement
in model preference of five commonly used model selection criteria. The model
Fig. 1 Model preference (percentage of all TACs) per selection criterion for the six brain PET radiotracers
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selection criteria evaluated are all based on similar assumptions, possibly explaining
that the choice for a certain model selection criterion hardly affected identification of
the preferred model. For a mathematical evaluation of the underlying assumptions of
model selection criteria and their considerations, see [22], [23], [24].
In short, small differences between criteria exist with respect to the penalty applied
for the number of parameters and observations (frames). AIC, AICC, SC, and MSC all
include an extra penalty term for the number of parameters, trying to account for the
possibility of over-fitting the model. The penalty used in AICC seems to be stronger
than that used in SC and MSC when compared to AIC. AIC becomes strongly biased
when the ratio of model parameters to observations (acquisition frames) increases, for
which AICC tries to correct. When the number of observations increases, AICC
converges to AIC. Due to the stronger penalty, AICC seems to prefer the models with
less parameters when the ratio is bigger. For [11C]FMZ and [11C]PHT, both with < 20
observations, AICC indeed preferred the model with less parameters slightly more
frequently compared with the other criteria. For [11C]PHT, this was reflected in a
Fig. 2 Model preference (percentage of all TACs ≥ 5 mL) per selection criterion for the six brain PET radiotracers
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regional disagreement between AIC and AICC of 16% of the TACs. For FMZ, this re-
sulted in AICC identifying a different kinetic model when examining all VOIs across all
subjects as illustrated in Fig. 1. However, this difference in model preference was
mainly driven by a single subject where AICC disagreed strongly with the other model
selection criteria, which was confirmed by the F-test. For the remaining four subjects,
AICC and F-test preferred the same model for FMZ as did the other criteria.
For [11C]PK11195, [11C]raclopride, [18F]FDG, and [11C]FMZ, the F-test did not agree
with AIC for only four individual (subject) cases (one subject from each tracer study). For
[11C]PHT and [11C]GMOM, the F-test agreed with AIC in all cases. The overall agree-
ment for all tracers and subjects was 87% between AIC and F-test. However, on a (tracer)
study level, this did not affect the model preference for that tracer. The F-test is designed
to directly compare two models and is especially suited for this purpose. AIC and MSC
yielded identical results. Compared with AIC, MSC includes normalization and is there-
fore independent of scaling of the data points. The normalization incorporated in MSC,
however, seems to have little effect for the data described in this study.
Fig. 3 Model preference (percentage of all TACs < 5 mL) per selection criterion for the six brain PET radiotracers
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Even though the model selection criteria showed strong overlap, it is not always
straightforward which model provides the best fit for the data. For example, ~ 30% of
all TACs clearly identified 2T4k_VB for [
18F]FDG, whereas the kinetics of all other
TACs were described by 2T3k_VB.
A total of 68 gray matter VOIs were included per subject, implying that the analysis
comprised of both receptor-rich and receptor-devoid VOIs (which varies depending on
the target of interest/tracer) and thus the observed regional differences in model prefer-
ences (Figs. 1, 2, and 3). In addition to the receptor density, another reason for regional
differences in the same subject for the same tracer could be the size of VOI. Smaller
VOI tends to have lower counts and thereby higher noise, which makes it difficult to
define the optimal pharmacokinetic model. Figure 2 illustrates the impact of noise on
the model selection when using different model selection criteria. Noise could be a
probable cause for the observed differences between Figs. 2 and 3.
Preferred model can be affected by several factors such as in vivo kinetics of the VOI
(underlying receptor density), subject status, input function (particularly parent fraction and
metabolites), tracer free fraction, motion, and even the scan duration. It should be noted
that a description of tracer kinetics and the identification of the preferred kinetic model
using model selection criteria is only one of the many evaluations needed to identify the op-
timal model. For example, in order to determine the optimal kinetic model, several other
datasets and studies are required such as test-retest data, data for both healthy controls and
diseased subjects, data correlating model results with pathology, and/or outcome (disease
duration, cognitive scores, or survival). Also, the intended application, e.g. differential diag-
nosis or response assessment, may or may not allow for the use of simplified models or
methods. Moreover, formulating a hypothesis on the preferred kinetic model based on
physiological properties of the tracer, e.g. derived from preclinical studies, is advised.
The number of subjects included for each tracer might be a limitation for this study;
however, typically first in man PET studies are limited in subject number and often
restricted to healthy subjects. In these circumstances, use of model selection criteria
provides a first indication of one or more suitable candidate kinetic models which
should be further developed and evaluated. Even though both healthy controls and
patients were included for the analysis, no impact on the conclusions is expected, as
over a wide range of kinetics with quite consistent results in the performance of the
various criteria was observed. Therefore, possible changes in tracer kinetics in healthy
versus diseased subjects would likely have little impact on the performance of these
criteria, but should be verified in individual cases.
Conclusions
All model selection criteria tested resulted in similar conclusions with only minor,
non-relevant differences in overall observed model preference.
Additional file
Additional file 1: Figure S1. Typical whole brain gray matter TACs of all the six brain PET radiotracers. (TIFF 43 kb)
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